A phase 1 study of KITE-363 anti-CD19/CD20 chimeric antigen receptor (CAR) T-cell therapy in patients (pts) with relapsed/refractory (R/R) B-cell lymphoma (BCL).
Year: 2025
Type: conference-abstract
Source: Journal of Clinical Oncology
Institutions: Stanford Medicine, Stanford University, Banner MD Anderson Cancer Center, Universitätsklinikum Würzburg, Amsterdam University Medical Centers, Cancer Center Amsterdam, University of Amsterdam, University of Maryland, Baltimore, University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, University of Rochester Medicine, Columbia University Irving Medical Center, King's College Hospital, The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State University, The University of Texas MD Anderson Cancer Center, Kite (United States)
Language: English
Topic: CAR-T cell therapy research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4410820965